Related Experiment Video
Updated: Jun 28, 2026

An All-Human Hepatic Culture System for Drug Development Applications
Published on: October 20, 2023
Discovering plausible mechanistic details of hepatic drug interactions
1The University of California, San Francisco Program in Pharmaceutical Sciences and Pharmacogenomics, San Francisco, California 94143-0912, USA.
Abstract:
We sought a single set of mechanisms that could provide a quantitative explanation of three pairs of published time series data: perfusate concentration of digoxin and its metabolite in perfusates of isolated perfused rat livers 1) in the absence of any predose and with a predose of either 2) the uptake inhibitor rifampicin or 3) the efflux inhibitor quinidine. We used the synthetic modeling and simulation method because it provides a means of developing a scientific, experimental approach to unraveling and understanding some of the complexities of drug-drug interactions. We plugged together validated, quasi-autonomous software components to form abstract but mechanistically realistic analogs of livers undergoing perfusion [recirculating in silico livers (RISLs)], into which we could add objects representing each of the above three drugs, alone or in combination. Each RISL was a hypothesis about plausible mechanisms responsible for the referent time series data. Simulations tested each hypothesis. We used similarity measures (SMs) to compare results to the six sets of referent data. From many candidates, we identified an RISL having time-invariant mechanisms that achieved a weak SM (SM-1) but failed to achieve a stronger SM. Replacing four time-invariant with time-variant mechanisms along with addition of new enzyme and transporter components achieved the most stringent SM: simulated digoxin and metabolite perfusate levels were experimentally indistinguishable from the referent data for all three treatments. The mechanisms simulated unanticipated loss of hepatic viability during the original wet-lab experiments: erosion of hepatic accessibility and of enzyme and transporter activities.
More Related Videos
10:44Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
14:34A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
Published on: April 3, 2026
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Pharmacokinetics: Drug–Drug Interactions
Drug toxicity: Drug–Drug Interaction